Francesca Boyte, Brighid Scanlon, Robyn Matthews, Elise Button, Lee Jones, Therese Hayes, Grant Partridge, Michael Smith, Glen Andrew Kennedy, Melissa Eastgate, Nicole Clare Gavin
{"title":"Bolusing IV Administration Sets With Monoclonal Antibodies Reduces Cost and Chair Time: A Randomized Controlled Trial.","authors":"Francesca Boyte, Brighid Scanlon, Robyn Matthews, Elise Button, Lee Jones, Therese Hayes, Grant Partridge, Michael Smith, Glen Andrew Kennedy, Melissa Eastgate, Nicole Clare Gavin","doi":"10.1188/24.CJON.E9-E15","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Monoclonal antibodies are widely used anticancer therapies. Increasing demand for ambulatory care necessitates exploration of efficiency measures.</p><p><strong>Objectives: </strong>The primary objective was to evaluate the impacts on chair time and associated cost of priming IV administration sets with a bolus of the prescribed monoclonal antibody drugs. A secondary objective was to assess the associated incidence of hypersensitivity reactions.</p><p><strong>Methods: </strong>A large tertiary hospital in Brisbane, Australia, conducted a randomized controlled trial (N = 128) with a two-arm design. Included monoclonal antibodies were daratumumab, obinutuzumab, pembrolizumab, and nivolumab.</p><p><strong>Findings: </strong>There was a statistically significant reduction in chair time for obinutuzumab, pembrolizumab, and nivolumab compared with the control. Findings suggest that this priming intervention reduces chair time and cost for some monoclonal antibody drugs. Future research could assess this practice in other oncology therapies.</p>","PeriodicalId":10350,"journal":{"name":"Clinical journal of oncology nursing","volume":null,"pages":null},"PeriodicalIF":1.3000,"publicationDate":"2024-09-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical journal of oncology nursing","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1188/24.CJON.E9-E15","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"NURSING","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Monoclonal antibodies are widely used anticancer therapies. Increasing demand for ambulatory care necessitates exploration of efficiency measures.
Objectives: The primary objective was to evaluate the impacts on chair time and associated cost of priming IV administration sets with a bolus of the prescribed monoclonal antibody drugs. A secondary objective was to assess the associated incidence of hypersensitivity reactions.
Methods: A large tertiary hospital in Brisbane, Australia, conducted a randomized controlled trial (N = 128) with a two-arm design. Included monoclonal antibodies were daratumumab, obinutuzumab, pembrolizumab, and nivolumab.
Findings: There was a statistically significant reduction in chair time for obinutuzumab, pembrolizumab, and nivolumab compared with the control. Findings suggest that this priming intervention reduces chair time and cost for some monoclonal antibody drugs. Future research could assess this practice in other oncology therapies.
期刊介绍：
The Clinical Journal of Oncology Nursing (CJON) is an official publication of the Oncology Nursing Society (ONS) and is directed to the practicing nurse specializing in the care of patients with an actual or potential diagnosis of cancer. CJON is a vehicle to promote the mission of ONS, which is to advance excellence in oncology nursing and quality cancer care. The CJON mission is twofold: to provide practical information necessary to care for patients and their families across the cancer continuum and to develop publication skills in oncology nurses.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
